Such preventive treatments are perfectly applicable in the context of CIPN, since chemotherapy protocols are planned in a hospital setting. human malignancy cell lines. The preventive treatment with hIg alleviated tactile hypersensitivity and nerve injuries induced by VCR. It also alleviated tactile/chilly hypersensitivities and nerve injuries induced by OXP. Treatment with hIg did not impact the cytotoxicity of either chemotherapy. Furthermore, in combination with VCR, hIg potentiated chemo-induced cell death. In conclusion, hIg is usually a encouraging therapy to prevent the onset of CIPN and potentiate chemotherapy effect on malignancy, reinforcing the interest in hIg in the management of CIPN. Keywords:chemotherapy, intravenous immunoglobulins, GSK3368715 dihydrochloride IVIG, neuropathic pain, malignancy, CIPN, mouse models, allodynia == 1. Introduction == The occurrence of peripheral neuropathy is usually a major dose-limiting effect for many commonly-used chemotherapeutic brokers, and it greatly affects patient quality of life. A meta-analysis of over 4000 patients receiving chemotherapy revealed that this prevalence of chemotherapy-induced peripheral neuropathy (CIPN) is around 68% during the first month post-treatment [1]. CIPNs are mainly length-dependent, and they are predominantly sensitive polyneuropathies that are either reversible or may persist for several years after cessation of the treatment. The most debilitating symptom is usually neuropathic pain which can have a GSK3368715 dihydrochloride particularly unfavorable impact on daily activities, and it represents one of the main causes of impaired quality of life in malignancy survivors [2]. In addition, more than half of patients with neuropathic pain develop mood disorders such as depressive disorder and stress, which are associated with a less favorable prognosis [3,4]. Thus, preventing the onset of CIPN and its progression through an appropriate therapeutic approach is a key priority for maintaining anticancer treatments and for improving patient quality of life during and after the end of chemotherapy. The pathophysiology is dependent around the agent, and the underlying molecular mechanisms remain unknown. However, an emerging concept concerns the involvement of immune-mediated mechanisms. At first, the injection of chemotherapeutic brokers has an immunosuppressive effect due to their cytotoxic effects on immune cells, although, increasing evidence suggests that neurotoxic chemotherapy likely stimulates inflammatory mechanisms that are responsible for CIPN [5]. An increase in cytokine levels, the activation of cytotoxic cells, and the recruitment of macrophages have all been described as being initiated by chemotherapeutic brokers such as vincristine (VCR) and oxaliplatin (OXP) [6,7,8,9]. Moreover, GSK3368715 dihydrochloride nerve lesions attract immune cells, which infiltrate the site of injury and could contribute to the maintenance of pain [10,11]. Recently, a meta-analysis showed that there may be a therapeutic advantage to using polyvalent human immunoglobulins (hIg) to CALCA alleviate pain caused by peripheral neuropathies. The results showed that 65% of patients with neuropathic pain who received hIg reported pain relief [12]. Moreover, hIg has been found to have anti-inflammatory effects by regulating cytokine levels, modulating the activity and quantity of immune cells, and by affecting NFB levels [13]. In addition, hIg is already used as a first-line therapy in the treatment of peripheral neuropathies such as GuillainBarr syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, and it is a well-tolerated treatment [14]. Therefore, we believe that hIg could be a encouraging therapy to prevent CIPN. Preclinical studies have already explained the neuroprotective effect of hIg in rat models of paclitaxel- and bortezomib-induced peripheral neuropathies [15,16]. Our goal, in this study, was to assess the neuroprotective effect of hIg on mouse models of VCR- and OXP-induced neuropathy, as well as to examine any impact of hIg around the cytotoxic effects of chemotherapy brokers in human cell lines. == 2. Materials and Methods == == 2.1. Chemicals == The anticancer brokers, VCR (vincristine Hospira, 2 mg/2 mL, Pfizer, New York, NY, USA) and OXP (oxaliplatin Hospira, 200 mg/40 mL, Pfizer, New York, NY, USA), were obtained from the Hospital Pharmacy of Limoges and diluted in a physiological answer (NaCl 0.9% in water for injection) for VCR, or in glucose 5% for OXP for animal experiments. Normal human immunoglobulins (hIg) were supplied by CSL Behring France (Privigen, 100 mg/mL, Paris, France) and diluted in saline answer. == 2.2. In Vivo Studies == == 2.2.1. Animals == This study was conducted in accordance with the guidelines for the ethical care of experimental animals of.